Seeking Alpha

Biotech analyst Adam Feurstein weighs in on the 10.5% premarket run in shares of BioSante...

Biotech analyst Adam Feurstein weighs in on the 10.5% premarket run in shares of BioSante Pharmaceuticals (BPAX) tied to the firm's announcement on its GVAX vaccine - calling out that the firm is "hyping" previously released data.
Comments (3)
  • herbert hoover
    , contributor
    Comments (2005) | Send Message
    Poor Adam is only allowed to say whatever Icahn tells him to say
    5 Mar 2012, 09:09 AM Reply Like
  • jdsrqdh
    , contributor
    Comments (2) | Send Message
    AF will you please provide investors with some information about Bpax cancer vaccines and why you feel they are "worthless"


    Starting at each of the 17 ongoing studies, Your thoughts as to why the FDA has granted 4 orphan drug designations ? why John Hopkins University has invested a decade of research for "Gvax" The recent results for Panc , and Today';s results on a P1 Prostate study....Do you feel that these results are useless? And have no value to the patients ? or stockholders?


    Regarding Libigel , What are your thoughts if Libigel receives FDA approval for "Safety" do you think there is any value ? Or chance they will eventually receive a FDA approval for Libi , And use the efficacy trial Bloom 1 & 2 results to model a new trial ? Your thoughts would be appreciated ........You are obviously entitled to your own opinion, Your readers deserve some explanation as to how you arrive at a "evaluation" of any company , In the absence of presenting some research, documentation to support what you are saying.


    Thank You
    5 Mar 2012, 02:49 PM Reply Like
  • T2nguyeninv1130
    , contributor
    Comment (1) | Send Message
    AF has all bad commends of BPAX. Nagative minds.....of somthings.
    7 Mar 2012, 01:18 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: